四月二十九日，美國國立衛生所首席病毒學家 Dr. Fauci（福奇）對美國民眾宣佈瑞德西韦的三期臨床試驗(800患者)結果顯示該藥可以使病人更快恢復，以及用藥越早，其效果越佳。
”Later Wednesday, White House health advisor Dr. Anthony Fauci said NIAID’s remdesivir drug trial, which enrolled about 800
patients, showed “quite good news” and that the drug would set a new standard of care for Covid-19 patients. Speaking to
reporters from the White House, Fauci said he was told data from the trial showed a “clear-cut positive effect in diminishing
time to recover.”
五月一日，FDA批准了瑞德西韋紧急使用授权。
"The Food and Drug Administration, in the meantime, has been in “sustained and ongoing” discussions with Gilead to make
remdesivir available to Covid-19 patients “as quickly as possible, as appropriate,” said FDA senior advisor Michael
Felberbaum.”
斯坦福大學醫院從三月初即開展了瑞德西韋的臨床試驗。四月二十九日，斯坦福大學參與了瑞德西韋臨床試驗的醫學研究員指出該藥與其他藥物而言，作為對治新冠病毒的藥物，有其明顯療效。
“Results from two eagerly awaited clinical trials of the experimental anti-viral drug remdesivir showed it is effective against
COVID-19, indicating for the first time the potential for medicines to help in the fight against the coronavirus pandemic.
“These two rigorously done trials provide really the first evidence of the efficacy of any therapeutic for this disease,” Lloyd
Minor, MD, dean of the Stanford School of Medicine, said April 29 during a university town hall meeting (SUNet ID required).
“I think this is very encouraging in terms of the future.”
美國第一例新冠病毒患者（自武漢返回西雅圖後），30 餘歲亞馬遜員工，於一月二十日確診，當病情惡化嚴重後，經過使用同情用藥審批，在注射了瑞德西韋後病情很快好轉，半月出院（全程機器人治療）。二月二十三日，法國波爾多醫學院用瑞德西韋治愈一 48 歲病患。二月二十六日，加大戴維斯分校醫療中心亦使用瑞德西韋對一瀕危老年患者治療，次日病情即顯著好轉。三月十日新澤西州首例確診患者請求使用瑞德西韋治療十日後康復出院。在洛杉磯、日本亦有使用瑞德西韋治愈重症患者案例。
與此同時，一月二十一日，武漢病毒所即買了瑞德西韋於中國的專利。而後在中國進行臨床試驗後卻因缺乏病例而宣告試驗失敗。這個只有區區兩百多病例樣本的試驗，卻在福奇宣佈瑞德西韋有效同時，國內知識界以各種鋪天蓋地的宣傳攻勢宣稱該藥物對新冠病毒”無效。“連病例都湊不足，卻對不知情的民眾誤導結果，這是有意為之，還是無意為之？武漢作為 Coronovirus Groud Zero, 竟然連病例都湊不齊（雙黃連、連花清瘟分流了病例），這不能不說是國家特色的悲哀了！
Ref:
1:https://www.cnbc.com/2020/04/29/gilead-reports-positive-data-on-remdesivir-coronavirus-drug-trial.html
2:http://med.stanford.edu/news/all-news/2020/05/remdesivir-gets-emergency-approval-from-fda-for-covid-19.html